Jiann Bang-Ping
Division of Basic Medical Research, Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Transl Androl Urol. 2016 Aug;5(4):526-40. doi: 10.21037/tau.2016.05.07.
Premature ejaculation (PE), delayed ejaculation (DE), anejaculation (AE) and retrograde ejaculation (RE) are four main ejaculatory disorders (EjDs) observed in clinical practice. Despite their high prevalence, EjDs remain underdiagnosed and undertreated. Primary care physicians should incorporate the discussion of sexual health topics into routine visits to facilitate EjD diagnosis and treatment. Because the causes of EjDs are multifactorial, the management of EjDs is etiology-specific and may require a holistic approach. Dapoxetine, a selective serotonin reuptake inhibitor, is the only drug approved for on-demand treatment of lifelong and acquired PE. In clinical practice, scheduled follow-up visits, risk factor treatment, appropriate dose escalation, adequate sexual attempts, patient education, and partner involvement are critical factors responsible for optimal overall management of PE and dapoxetine treatment outcomes.
早泄(PE)、射精延迟(DE)、无射精(AE)和逆行射精(RE)是临床实践中观察到的四种主要射精障碍(EjDs)。尽管其患病率很高,但射精障碍仍未得到充分诊断和治疗。初级保健医生应将性健康话题的讨论纳入常规就诊,以促进射精障碍的诊断和治疗。由于射精障碍的病因是多因素的,射精障碍的管理是针对病因的,可能需要整体方法。达泊西汀是一种选择性5-羟色胺再摄取抑制剂,是唯一被批准用于按需治疗终身性和获得性早泄的药物。在临床实践中,定期随访、危险因素治疗、适当的剂量递增、足够的性尝试、患者教育和伴侣参与是对早泄的最佳整体管理和达泊西汀治疗结果负责的关键因素。